Miravant Purlytin PDT For Macular Degeneration Entering Phase II/III
This article was originally published in The Gray Sheet
Executive Summary
Miravant expects to begin Phase II/III trials for Purlytin (SnET2, tin ethyl etiopurpurin) for age-related macular degeneration in the second quarter of 1998.